ANAVEX LIFE SCIENCES CORP (AVXL) Fundamental Analysis & Valuation
NASDAQ:AVXL • US0327973006
Current stock price
3.37 USD
+0.08 (+2.43%)
At close:
3.37 USD
0 (0%)
After Hours:
This AVXL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AVXL Profitability Analysis
1.1 Basic Checks
- In the past year AVXL has reported negative net income.
- In the past year AVXL has reported a negative cash flow from operations.
- AVXL had negative earnings in each of the past 5 years.
- AVXL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- AVXL's Return On Assets of -30.04% is fine compared to the rest of the industry. AVXL outperforms 65.44% of its industry peers.
- The Return On Equity of AVXL (-31.55%) is better than 74.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.04% | ||
| ROE | -31.55% | ||
| ROIC | N/A |
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for AVXL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. AVXL Health Analysis
2.1 Basic Checks
- The number of shares outstanding for AVXL has been increased compared to 1 year ago.
- AVXL has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for AVXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- AVXL has an Altman-Z score of 25.36. This indicates that AVXL is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 25.36, AVXL belongs to the top of the industry, outperforming 90.68% of the companies in the same industry.
- AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 25.36 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- AVXL has a Current Ratio of 20.87. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 20.87, AVXL belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
- AVXL has a Quick Ratio of 20.87. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 20.87, AVXL belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 20.87 | ||
| Quick Ratio | 20.87 |
3. AVXL Growth Analysis
3.1 Past
- AVXL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.36%, which is quite good.
EPS 1Y (TTM)16.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- AVXL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.04% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.61%
EPS Next 2Y31.74%
EPS Next 3Y84.57%
EPS Next 5Y64.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. AVXL Valuation Analysis
4.1 Price/Earnings Ratio
- AVXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVXL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as AVXL's earnings are expected to grow with 84.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.74%
EPS Next 3Y84.57%
5. AVXL Dividend Analysis
5.1 Amount
- AVXL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AVXL Fundamentals: All Metrics, Ratios and Statistics
3.37
+0.08 (+2.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.66
Earnings (Last)02-09 2026-02-09/bmo
Earnings (Next)05-07 2026-05-07
Inst Owners41.54%
Inst Owner Change0.06%
Ins Owners3.12%
Ins Owner Change0%
Market Cap312.30M
Revenue(TTM)N/A
Net Income(TTM)-39.95M
Analysts80
Price Target22.44 (565.88%)
Short Float %21.11%
Short Ratio13.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.31%
Min EPS beat(2)28.1%
Max EPS beat(2)46.52%
EPS beat(4)3
Avg EPS beat(4)20.05%
Min EPS beat(4)-9.44%
Max EPS beat(4)46.52%
EPS beat(8)6
Avg EPS beat(8)14.22%
EPS beat(12)10
Avg EPS beat(12)15.63%
EPS beat(16)12
Avg EPS beat(16)12.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.78%
EPS NY rev (1m)0%
EPS NY rev (3m)32.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.47 | ||
| P/tB | 2.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS1.37
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.04% | ||
| ROE | -31.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 20.87 | ||
| Quick Ratio | 20.87 | ||
| Altman-Z | 25.36 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y38.61%
EPS Next 2Y31.74%
EPS Next 3Y84.57%
EPS Next 5Y64.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1044.8%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.25%
OCF growth 3YN/A
OCF growth 5YN/A
ANAVEX LIFE SCIENCES CORP / AVXL Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ANAVEX LIFE SCIENCES CORP?
ChartMill assigns a fundamental rating of 3 / 10 to AVXL.
What is the valuation status for AVXL stock?
ChartMill assigns a valuation rating of 1 / 10 to ANAVEX LIFE SCIENCES CORP (AVXL). This can be considered as Overvalued.
How profitable is ANAVEX LIFE SCIENCES CORP (AVXL) stock?
ANAVEX LIFE SCIENCES CORP (AVXL) has a profitability rating of 1 / 10.